SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Studien-Informationen

Ein-/Ausschlusskriterien

Studien-Rationale

Studien-Arme

• RP-1828 IMMUcan
  The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary
• RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)
  The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS
• RP-1843 Arcagen (CLOSED for recruitment since November 2022)
  This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population. Tumor types: all 10 EURACAN domains
• RP-1920 BioRadon
  The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon). Tumor type: Thorax

Geprüfte Regime

• RP-1828 IMMUcan:
  WES, lcWGS and RNAseq, multiplex IF and IMC
• RP-1759 AYA/TYA:
  WES, RNAseq and EPIC array
• RP-1843 Arcagen:
  NGS panel
• RP-1920 BioRadon:
  NGS panel

Quelle: ClinicalTrials.gov